Drug Trial Radar · NCT03161353
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
Last checked: Nov 20, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
377
Actual
Start
Jun 26, 2017
Primary completion
Nov 1, 2023
Study completion Nov 1, 2026
Sponsor
- Lead sponsor
- MedSIRAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla. And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.
Conditions
- Breast Cancer
Interventions
PerjetaDrug
All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
HerceptinDrug
All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
DocetaxelDrug
Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
CarboplatinDrug
Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
LetrozoleDrug
Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
TamoxifenDrug
Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy. Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the rate of pCRTime frame: After Cycle 6 or 8 (each cycle 21 days- After 4.2 or 5.6 months)
- 3-year iDFS rateTime frame: After 3 years (36 months)
Locations
56 sites in 7 countries. Site status is shown where the registry gives one.
Institute Jules Bordet
Brussels, Belgium
CLCC d'Auvergne. Centre Jean Perrin.
Clermont-Ferrand, France
Institute de Cancerologie de Laurraine
Nancy, France
Groupe Hospitalier Diaconesses
Paris, France
Hopital Tenon
Paris, France
Hospital Georges Pompidou
Paris, France
Centre Paul Strauss
Strasbourg, France
Institut Claudius Régaud
Toulouse, France
Kliniken Essen Mitte
Essen, Germany
Klinikum der Med. Fakultät Halle
Halle, Germany
National center for tumor disease NCT
Heidelberg, Germany
Städtisches Klinikum "St. Georg" Leipzig
Leipzig, Germany
Hämatologisch-Onkologische Schwerpunktpraxis
München, Germany
Clinical of Nuclear Medicine Technical University Munich
Munich, Germany
Ospedale Maggiore Bologna
Bologna, Italy
Ospedale Antonio Perrino
Brindisi, Italy
Istituto Ospedalieri di Cremona
Cremona, Italy
Ospedale Mantova
Mantua, Italy
Istituto Europeo di Oncologia
Milan, Italy
Ospedale San Gerardo
Monza, Italy
Ospedale Guglielmo de Saliceto
Piacenza, Italy
Hospital Senhora da Oliveira
Guimarães, Portugal
Hospital Beatriz Angelo
Lisbon, Portugal
Hospital da Luz
Lisbon, Portugal
Hospital Fernando Fonseca
Lisbon, Portugal
Centro Hospitalar Sao Joao
Porto, Portugal
Hospital do Santo Antonio
Porto, Portugal
Centro Hospitalaer de Tras-os-Montes e Alto Douro
Vila Real, Portugal
Hospital Universitario A Coruña
A Coruña, Spain
Hospital Vall D'Hebrón
Barcelona, Spain
Hospital Clínic i Provincial de Barcelona
Barcelona, Spain
Hospital Universitario de Burgos
Burgos, Spain
Hospital Reina Sofía
Córdoba, Spain
ICO Girona
Girona, Spain
Hospital Arnau de Vilanova
Lleida, Spain
Hospital La Paz
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
CHUS Santiago de Compostela
Santiago de Compostela, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Hospital Arnau de Vilanova
Valencia, Spain
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.